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OBJECTIVE: This study aimed to identify novel GATA5 mutations that underlie familial atrial fibrillation.
METHODS: A total of 110 unrelated patients with familial atrial fibrillation and 200 unrelated, ethnically matched
healthy controls were recruited. The entire coding region of the GATA5 gene was sequenced in 110 atrial fibrillation
probands. The available relatives of the mutation carriers and 200 controls were subsequently genotyped for the
identified mutations. The functional effect of the mutated GATA5 was characterized using a luciferase reporter
assay system.
RESULTS: Two novel heterozygous GATA5 mutations (p.Y138F and p.C210G) were identified in two of the 110
unrelated atrial fibrillation families. These missense mutations cosegregated with AF in the families and were absent
in the 400 control chromosomes. A cross-species alignment of GATA5 protein sequence showed that the altered
amino acids were completely conserved evolutionarily. A functional analysis revealed that the mutant GATA5
proteins were associated with significantly decreased transcriptional activation when compared with their wild-type
counterpart.
CONCLUSION: The findings expand the spectrum of GATA5 mutations linked to AF and provide novel insights into
the molecular mechanism involved in the pathogenesis of atrial fibrillation, suggesting potential implications for
the early prophylaxis and personalized treatment of this common arrhythmia.
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INTRODUCTION
Atrial fibrillation (AF) is the most common form of
cardiac arrhythmia seen in clinical practice, accounting for
approximately one-third of hospitalizations for cardiac
rhythm disturbances. The prevalence of AF increases
markedly with advancing age, ranging from 1 to 2% of the
general population to 5 to 15% of individuals in their 80s (1).
The lifetime risk of developing AF is approximately 25% in
individuals aged 40 years or older (2). The chaotic heart
rhythm is responsible for a variety of symptoms, including
palpitations, dizziness, and shortness of breath, and it is
associated with degraded quality of life, reduced exercise
capacity, cognitive dysfunction, tachycardiomyopathy,
thromboembolic strokes, congestive heart failure, and even
death (1,3,4). The mortality rate of patients with AF is
approximately two times that of subjects with a normal
sinus rhythm (5). The rate of ischemic stroke among patients
with AF averages 5% per year, 2 to 7 times that of
individuals without AF (6). Additionally, when transient
ischemic attacks and clinically ‘‘silent’’ strokes documented
by brain imaging are included, the rate of cerebral ischemia
accompanying nonvalvular AF exceeds 7% per year (7).
Among the patients in the Framingham Heart Study with
rheumatic heart disease and AF, the stroke risk was
increased 17-fold compared with age-matched controls (8).
Given the frequency of comorbidities, AF imposes a huge
economic burden on both the individual and society as a
whole, and the economic burden for society is expected to
increase in the near future due to the aging population (9).
Despite the high prevalence and clinical significance of AF,
its underlying molecular etiology remains largely unknown.
AF can occur in the context of various structural heart
diseases or systemic disorders, including ischemic heart
disease, valvular heart disease, congenital heart disease,
cardiomyopathy, cardiac surgery, pericarditis, myocarditis,
congestive heart failure, essential hypertension, diabetes
mellitus, hyperthyroidism, and electrolyte imbalance
(1,10,11). However, in 30 to 45% of the cases, especially
among those younger than 60 years old, AF occurs without
any known risk factors, a condition known as ‘‘lone AF’’. At
least 15% of patients have a positive family history and are
considered to have familial AF (12). Accumulating evidence
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from epidemiological studies highlights the familial aggre-
gation of AF and the increased risk of AF among the close
relatives of patients with AF, strongly suggesting a
hereditary determinant for AF (13-15). Following genome-
wide linkage analysis with polymorphic genetic markers,
specific susceptibility loci for AF have been mapped to
human chromosomes 10q22, 6q14–16, 11p15.5, 5p15, 10p11–
q21, and 5p13, and AF-causing mutations in two genes,
KCNQ1 on chromosome 11p15.5 and NUP155 on chromo-
some 5p13, have been identified and characterized (16).
Analyses of candidate genes and genome-wide association
studies have revealed a long list of AF-associated genes,
including KCNE2, KCNH2, KCNA5, KCNJ2, KCNN3, GJA1,
GJA5, NPPA, ZFHX3, and SCN5A (16). Nevertheless, AF
demonstrates substantial genetic heterogeneity, and the
genetic defects that lead to AF in an overwhelming majority
of patients have not yet been identified.
It is now well established that abnormal embryological
development of the myocardial sleeves clothing the sys-
temic venous tributaries and the pulmonary veins at their
junctions with the atrial chambers is a major anatomic defect
associated with AF (17). Recent studies underline the pivotal
role of several transcription factors, including NKX2-5,
GATA4, GATA5, and GATA6, during cardiogenesis (18),
and mutations in NKX2-5, GATA4, and GATA6 have been
causally implicated in the pathogenesis of AF (19-24).
GATA5 is a member of the GATA family of transcription
factors, and its expression and functions overlap with those
of GATA4 and GATA6 during cardiac development,
especially the synergistic regulation of target gene expres-
sion with NKX2-5. This relationship provides a logical
rationale for screening GATA5 as a candidate gene
associated with familial AF (25).
MATERIALS AND METHODS
Ethics statement
This study was performed in compliance with the ethical
principles of the revised Declaration of Helsinki (Somerset
West, Republic of South Africa, 1996). The research protocol
was reviewed and approved by the local institutional ethics
committee, and written informed consent was obtained
from all participants prior to the study.
Study participants
A cohort of 110 unrelated probands with familial AF was
identified among the Chinese Han population. The available
relatives of the probands who harbored the identified
GATA5 mutations were also included. A total of 200
ethnically matched unrelated healthy individuals were
recruited as controls. Peripheral venous blood specimens
and clinical data, including medical records and electro-
cardiogram (ECG) and echocardiography reports, were
collected. The study subjects were clinically classified using
a consistently applied set of definitions (12). Briefly, AF was
diagnosed when ECGs demonstrated no P waves and
irregular R-R intervals, regardless of clinical symptoms.
Lone AF was defined as AF that occurred in individuals less
than 60 years of age without evidence of other cardiac or
systemic diseases after physical examination, ECG, trans-
thoracic echocardiogram, and extensive laboratory tests.
Familial AF was designated when lone AF occurred in one
or more first-degree relatives of the proband. Relatives were
classified as ‘unaffected’ if they were asymptomatic and had
a normal ECG. In addition, paroxysmal AF was defined as
AF that lasted more than 30 seconds and terminated
spontaneously. Persistent AF was defined as AF that lasted
more than seven days and required either pharmacologic
therapy or electrical cardioversion for termination. AF that
was refractory to cardioversion or that was allowed to
continue was classified as permanent.
Genetic studies
Genomic DNA from all participants was extracted from
peripheral venous blood lymphocytes using the Wizard
Genomic DNA Purification Kit (Promega, Madison, WI,
USA). The entire coding region and the flanking splice
junction sites of GATA5 were sequenced in 110 unrelated
index patients with familial AF, and GATA5 genotyping
was conducted for the available relatives of mutation
carriers and 200 ethnically matched unrelated healthy
controls to determine the presence of the mutations
identified in the probands. The reference genomic DNA
sequence of GATA5 was obtained from GenBank (accession
No. NT_011362). The primer pairs used to amplify the
coding exons and exon/intron boundaries of GATA5 using
polymerase chain reaction (PCR) were designed as pre-
viously described using Primer 3 software (http://frodo.wi.
mit.edu), (26). PCR was performed using HotStar Taq DNA
Polymerase (Qiagen GmbH, Hilden, Germany) on a PE 9700
Thermal Cycler (Applied Biosystems, Foster, CA, USA). The
amplicons were purified with a QIAquick Gel Extraction
Kit (Qiagen), and both strands of each PCR product
were sequenced using a BigDyeH Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems) and an ABI PRISM
3130 XL DNA Analyzer (Applied Biosystems). The DNA
sequences were analyzed with the DNA Sequencing
Analysis Software v5.1 (Applied Biosystems). The variant
was validated by resequencing an independent PCR-
generated amplicon from the subject, and it met our quality
control thresholds with a call rate greater than 99%.
Alignment of multiple GATA5 protein sequences
Multiple GATA5 protein sequences across various species
were aligned using the online program MUSCLE, Version
3.6 (http://www.ncbi.nlm.nih.gov/).
Construction of the recombinant pcDNA3.1-
hGATA5 expression plasmid
Human fetal cardiac tissue specimens were previously
collected and preserved in RNAlater RNA stabilization
reagent (Qiagen). Total RNA was prepared using an RNeasy
Protect Mini Kit (Qiagen). Reverse transcription was
performed with an oligo(dT)20 primer using SuperScript
III reverse transcriptase (Invitrogen, Carlsbad, CA, USA).
The full-length wild-type human GATA5 cDNA, including
partial 5’- and 3’-untranslated regions, was PCR amplified
using pfuUltra high-fidelity DNA polymerase (Stratagene,
La Jolla, CA, USA). The following primer pairs were used
for the specific amplification of the GATA5 transcript:
forward, 5’-GTA, GCT, AGC, CAC, CGC, CGT, GCC,
CTG, CCG-3’, and reverse, 5’-GAT, GCG, GCC, GCT,
GTT, CCC, CTG, ACA, TGG, GC-3’. A 1296-base pair PCR
fragment was digested with the endonucleases NheI and
NotI (TaKaRa, Dalian, Liaoning, China). The digested product
was fractionated using 1.5% agarose gel electrophoresis,
purified using a QIAquick Gel Extraction Kit (Qiagen), and
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then subcloned into pcDNA3.1 (Promega) to generate the
eukaryotic expression vector, pcDNA3.1-hGATA5.
Site-directed mutagenesis
The identified mutation was introduced into wild-
type GATA5 using a QuickChange II XL Site-Directed
Mutagenesis Kit (Stratagene) with a complementary pair of
primers. The mutant was sequenced to confirm the desired
mutation and to exclude any other sequence variations.
Reporter gene assay
The atrial natriuretic factor (ANF)-luciferase reporter
construct (ANF(-2600)-Luc), which contains the 2600-bp 5’-
flanking region of the ANF gene, was graciously provided
by Dr. Ichiro Shiojima from Chiba University School of
Medicine (Chiba-shi, Chiba, Japan). HEK-293 cells were
cultured in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal calf serum. The ANF(-2600)-Luc
reporter construct and an internal control reporter plasmid
pGL4.75 (hRluc/CMV, Promega), were used in transient
transfection assays to examine the transcriptional activation
activity of the GATA5 mutant. HEK-293 cells were trans-
fected with 0.4 mg of wild-type or mutant pcDNA3.1-
hGATA5, 0.4 mg of the ANF(-2600)-Luc reporter construct,
and 0.04 mg of the pGL4.75 control reporter vector using
PolyFect Transfection Reagent (Qiagen). For the cotransfec-
tion experiments, 0.2 mg of wild-type pcDNA3.1-hGATA5,
0.2 mg of mutant pcDNA3.1-hGATA5, 0.4 mg of ANF(-2600)-
Luc, and 0.04 mg of pGL4.75 were used. Firefly luciferase
and Renilla luciferase activities were measured using the
Dual-Glo luciferase assay system (Promega) 48 h after
transfection. The activity of the ANF promoter is presented
as the fold activation of Firefly luciferase relative to Renilla
luciferase. A minimum of three independent experiments
were performed for wild-type and mutant GATA5.
Statistical analysis
The data are expressed as the mean ¡ SD. Continuous
variables were tested for normality of distribution, and
Student’s unpaired t-test was used to compare numeric
variables between two groups. The categorical variables were
compared between two groups using Pearson’s chi-squared
test or Fisher’s exact test, when appropriate. A two-sided p-
value less than 0.05 was considered statistically significant.
RESULTS
Clinical characteristics of the study population
A cohort of 110 unrelated index patients with familial AF
was enrolled, clinically evaluated and compared with 200
ethnically matched, unrelated healthy individuals. None of the
subjects had traditional risk factors for AF. There were no
significant differences between the proband and control
groups in baseline characteristics, including age, gender, body
mass index, blood pressure, fasting blood glucose, serum lipid
levels, left atrial dimension, left ventricular ejection fraction,
and heart rate at rest. The baseline clinical characteristics of the
110 probands with familial AF are listed in Table 1.
GATA5 mutations
Two heterozygous missense mutations in GATA5 were
identified in two of 110 unrelated probands. The total
population prevalence of GATA5 mutations based on the
proband cohort was approximately 1.82%. Specifically, a
thymine to adenine transversion in the second nucleotide of
codon 138 (c.413ART), resulting in a tyrosine (Y) to
phenylalanine (F) substitution at amino acid 138 (p.Y138F),
was identified in the proband from Family 1. A thymine to
guanine transversion in the first nucleotide of codon 210
(c.628TRG), corresponding to a cysteine (C) to glycine (G)
substitution at amino acid 210 (p.C210G), was discovered in
the proband from Family 2. The sequence chromatograms
showing the detected heterozygous GATA5 mutations of
c.413ART and c.628TRG in contrast to control sequences are
shown in Figure 1. The two variants were not observed
in the 400 control alleles nor were they found in the
NCBI SNP database (http://www.ncbi.nlm.nih.gov/SNP).
Genetic scans of each family showed that the variation was
present in all affected living family members but absent in the
unaffected family members who were examined. An analysis
of the pedigrees demonstrated that in each family, the
mutation cosegregated with AF, which was transmitted in an
autosomal dominant pattern with complete penetrance. The
pedigrees of the two families are illustrated in Figure 2. The
phenotypic characteristics and genetic screening results for
the affected family members are summarized in Table 2.
Alignments of GATA5 protein sequences from
multiple species
A cross-species alignment of GATA5 protein sequences
showed that the altered amino acids were completely
conserved evolutionarily (Figure 3), suggesting that these
amino acids are functionally important.
Transcriptional activity of the GATA5 mutants
Wild-type GATA5, Y138F-mutant GATA5, and C210G-
mutant GATA5 increased the transcriptional activity of the
ANF promoter approximately 13-fold, 5-fold, and 2-fold,
respectively. When wild-type GATA5 was coexpressed with
the same amount of Y138F-mutant GATA5 or C210G-
mutant GATA5, the transcriptional activity of the ANF
promoter was increased approximately 7-fold and 4-fold,
respectively. These results reveal that each of the two
Table 1 - Baseline clinical characteristics of the 110
probands with familial atrial fibrillation.
Parameter n or mean % or range
Male 65 59
Age of onset 45.3 22–59
Paroxysmal atrial fibrillation on presentation 82 75
Progression to permanent atrial fibrillation 24 22
History of cardioversion 72 65
History of pacemaker 7 6
Resting heart rate (bpm) 75.6 50–160
Systolic blood pressure (mmHg) 125.2 90–136
Diastolic blood pressure (mmHg) 82.8 60–88
Body mass index (kg/m2) 22.1 20–24
Left atrial dimension (mm) 38 26–40
left ventricular ejection fraction 0.6 0.5–0.7
Fasting blood glucose (mmol/L) 4.6 3.6–5.8
Total cholesterol (mmol/L) 3.5 3.2–5.5
Triglycerides (mmol/L) 1.2 0.7–1.6
Medications
Amiodarone 68 62
Warfarin 62 56
Beta blocker 16 15
Calcium channel blocker 23 21
Digoxin 26 24
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GATA5 mutations is associated with significantly reduced
activation activity when compared with wild-type GATA5
(Figure 4).
DISCUSSION
In the present study, we report two novel heterozygous
missense mutations of GATA5 identified in two AF families.
In each family, the mutant allele is present in all of the
affected living family members but absent in the unaffected
relatives who were examined and in the 400 control
chromosomes. A cross-species alignment of GATA5 protein
sequences demonstrated that the altered amino acids are
completely conserved evolutionarily. The functional analysis
demonstrated that the mutant GATA5 proteins are associated
with significantly decreased transcriptional activation.
Therefore, it is very likely that functionally impaired
GATA5 is responsible for AF in these families. Given recently
reported GATA5 mutations in a larger cohort of AF patients
(26), GATA5 mutations may be a relatively common
molecular defect associated with the pathogenesis of AF.
GATA transcription factors are a group of zinc finger–
containing, DNA-binding proteins characterized by their
ability to bind to the consensus DNA sequence "GATA". In
vertebrates, the GATA family comprises six members
(GATA1–6), of which GATA4–6 are expressed in various
mesoderm- and endoderm-derived tissues, especially in the
embryonic heart (18). The GATA5 gene maps to human
chromosome 20q13.33 by fluorescence in situ hybridization
and encodes a 397–amino acid protein (27). An alignment of
GATA5 with GATA4 suggests that the structural domains
associated with GATA5 function consist of two transcrip-
tional activation domains (TAD1: 1–49; TAD2: 107–154), two
adjacent zinc fingers (ZF1: 187–212; ZF2: 242–266), and one
nuclear localization signal (NLS: 226–296). The two TADs
are both important to the transcriptional activity of GATA5.
The C-terminal ZF is essential for DNA sequence recogni-
tion and binding to the consensus motif, whereas the N-
terminal ZF is crucial for the stability and sequence
specificity of protein-DNA binding and transcriptional
activation by GATA factors. Most of the protein–protein
interactions of GATA factors are mediated by their C-
terminal ZF. The NLS sequence is associated with the
subcellular trafficking and distribution of GATA5. The
p.Y138F and p.C210G GATA5 mutations identified in this
study are located in the TAD2 and ZF1, respectively; thus,
they may affect the transcriptional activity of GATA5.
It has been demonstrated that GATA5 is an upstream
regulator of multiple genes expressed during embryogenesis,
Figure 1 - Sequence electropherograms showing the GATA5 mutations in contrast with their corresponding controls. The arrow
indicates the heterozygous A/T (Figure 1A) and T/G (Figure 1B) nucleotides in the probands from Families 1 and 2, respectively, (mutant)
or the homozygous A/A (Figure 1A) and T/T (Figure 1B) nucleotides in the corresponding controls (wild-type). The square denotes the
nucleotides comprising a GATA5 codon.
Figure 2 - The pedigrees of the families with atrial fibrillation. The
families are designated as Family 1 and Family 2. Family members
are identified by generation and number. Squares indicate male
family members; circles, female members; a symbol with a slash, a
deceased member; closed symbols, affected members; open
symbols, unaffected members; arrows, probands; ‘‘+’’, carriers of
the heterozygous mutations; and ‘‘2’’, non-carriers.
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including the genes that encode atrial natriuretic factor
(ANF), brain natriuretic peptide, a myosin heavy chain, b
myosin heavy chain, and cardiac troponin C and I (18).
Hence, the functional effect of the identified GATA5 muta-
tions can be explored by analyzing the transcriptional activity
of the ANF promoter in cells transfected with a GATA5
mutant or its wild-type counterpart. In this study, the
functional characteristics of the novel GATA5 mutations
identified in our familial AF patients (p.Y138F and p.C210G)
were investigated using transcriptional activity assays,
and the significantly reduced transcriptional activity was
observed following the expression of the mutant proteins.
These findings indicate that dysfunctional GATA5 is poten-
tially an alternative pathological mechanism involved in AF,
although the functional roles of the recently reported AF-
associated GATA5 mutations remain to be addressed (26).
The findings that dysfunctional GATA5 confers suscept-
ibility to AF may be partially attributable to the abnormal
development of the pulmonary venous myocardium. The
pulmonary venous vessel is surrounded by a layer of
myocardium known as the pulmonary myocardial sleeve,
which is believed to be responsible for the initiation and
maintenance of AF by several potential arrhythmogenic
mechanisms that favor reentry, including enhanced intrinsic
pacemaker activity, anisotropic arrangement of the myocar-
dial fibers and slowed conduction (28-30). Genetic-labeling
lineage-tracing studies have demonstrated that NKX2-5 is
expressed in the atria and pulmonary myocardium and is
important in the localization of the sinoatrial node during
embryogenesis. NKX2-5 may act as a repressor of the
sinoatrial node lineage gene program, limiting pacemaker
activity to the sinoatrial and atrioventricular nodes. When
NKX2-5 expression decreased in a hypomorphic model, the
pulmonary cardiomyocytes switched to connexin40-nega-
tive, HCN4-positive cells, a nodal-like phenotype with
pacemaker activity (30). In NKX2-5 knockout mouse
Table 2 - Phenotypic characteristics and the GATA5 mutation status of the affected pedigree members.
Subject Information Phenotype Electrocardiogram Echocardiogram Genotype
Identity Gender
Age at time of
study (years)
Age at first diagnosis
of AF (years)
AF
(classification)
QRS interval
(ms) QT / QTc
LAD
(mm)
LVEF
(%)
GATA5
mutations
Family 1 Y138F
I-2 F 75 44 Permanent 98 398/417 40 60 +/–
II-1 M 52 38 Paroxysmal 92 350/458 35 68 +/–
II-6 F 46 42 Persistent 90 368/405 32 65 +/–
III-1 F 26 25 Paroxysmal 88 372/437 28 64 +/–
Family 2 C210G
I-1 M 72a 45 Permanent 102 362/420 42 58 N/A
II-3 M 50 32 Paroxysmal 98 414/443 35 66 +/–
III-2 F 24 24 Paroxysmal 90 356/452 30 62 +/–
Note: AF = atrial fibrillation; F = female; M = male; N/A = not available or not applicable; LAD = left atrial dimension; LVEF = left ventricular ejection
fraction; QT = QT interval; QTc = corrected QT interval. + indicates present and – denotes absent. a Age at death.
Figure 3 - Alignment of the GATA5 protein sequence of multiple species. The amino acids altered as a result of the described mutations
(p.Y138 and p.C210) are completely conserved evolutionarily.
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embryos, HCN4 was overexpressed in the whole embryonic
heart, whereas connexin40 expression was suppressed and
ectopic pacemaker cells were observed throughout the heart
tube (31). In humans, AF has been observed as an isolated
phenotype or as a part of compound phenotypes in patients
carrying NKX2-5 mutations (32-34). Therefore, as a transcrip-
tional cooperative partner of NKX2-5 (29), GATA5, when
loss-of-function mutations occur, may contribute to the
altered formation of the pulmonary myocardium sleeve
and the shift of the pulmonary myocardium to a sinoatrial
node–like phenotype, hence creating an electrophysiological
substrate for AF.
Some downstream genes are upregulated by GATA5, and
mutations in several target genes have been associated with
AF, including the ANF genes (35). Therefore, it is likely that
mutated GATA5 predisposes affected individuals to AF by
downregulating the expression of these target genes.
In conclusion, the present investigation links GATA5 loss-
of-function mutations to familial AF and provides novel
insights into the molecular mechanisms involved in the
pathogenesis of AF. Furthermore, these results have
potential implications for early prophylactic therapies and
personalized treatment for AF.
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